(6-Chloropyridin-3-yl)(2-methylpiperidin-1-yl)methanone

Catalog No. :
ACRVZO307
CAS No. :
385408-28-6
Molecular Formula :
C12H15ClN2O
Molecular Weight :
238.72

IUPAC Name:(6-chloropyridin-3-yl)(2-methylpiperidin-1-yl)methanone

(6-Chloropyridin-3-yl)(2-methylpiperidin-1-yl)methanone structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg98%$172.00Login to see priceIn stockInquiry
1g98%$463.00Login to see priceIn stockInquiry
5g98%$1623.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name(6-Chloropyridin-3-yl)(2-methylpiperidin-1-yl)methanone
IUPAC Name(6-chloropyridin-3-yl)(2-methylpiperidin-1-yl)methanone
Molecular FormulaC12H15ClN2O
Molecular Weight238.72
SMILESCC1CCCCN1C(C2=CN=C(Cl)C=C2)=O
InChI KeyXCBFDGHHGVSHQB-UHFFFAOYSA-N
SynonymMethanone, (6-chloro-3-pyridinyl)(2-methyl-1-piperidinyl)-;(6-Chloropyridin-3-yl)(2-methylpiperidin-1-yl)methanone;1-[(6-CHLORO-3-PYRIDINYL)CARBONYL]-2-METHYLPIPERIDINE
CAS No.385408-28-6
PubChem CID4001082

Safety Data

Pictogram
Toxic
Signal Word
Gefahr
Hazard Statement(s)
H301-H311-H331
Precautionary Statement(s)
P261-P264-P270-P271-P280-P302+P352-P304+P340-P310-P330-P361-P403+P233-P405-P501

Synthetic Route by SureRoute

1. ACRVZO307 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACVWZJ540 route compound structure diagram
    ACVWZJ5405326-23-8 In Stock
  4. Then
  5. ACRVZO307 route product structure diagram
    ACRVZO307385408-28-6 In Stock
Inquiry

2. ACRVZO307 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Plus
  3. ACFKDZ140 route compound structure diagram
    ACFKDZ14058757-38-3 In Stock
  4. Then
  5. ACRVZO307 route product structure diagram
    ACRVZO307385408-28-6 In Stock
Inquiry

Comments (0)